Gout

BMJ (Online)

Volumn 347, Issue 7927, 2013, Pages

  Roddy, Edward ^a   Mallen, Christian D ^a   Doherty, Michael ^b  

^a KEELE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMIODARONE; BENZBROMARONE; COLCHICINE; CYCLOSPORIN A; DIGOXIN; DILTIAZEM; ETORICOXIB; FEBUXOSTAT; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDOMETACIN; ITRACONAZOLE; KETOCONAZOLE; MACROLIDE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISOLONE; PROBENECID; PROTEINASE INHIBITOR; SULFINPYRAZONE; URIC ACID; VERAPAMIL;

CLINICAL ASSESSMENT; CLINICAL FEATURE; DIAGNOSTIC TEST; DIARRHEA; DISEASE ASSOCIATION; DRESS SYNDROME; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG INDICATION; DRUG MEGADOSE; GASTROINTESTINAL SYMPTOM; GOUT; HUMAN; KIDNEY FAILURE; LOW DRUG DOSE; METATARSOPHALANGEAL JOINT; PATHOGENESIS; PATIENT CARE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; URIC ACID BLOOD LEVEL; VOMITING;

EID: 84885167100     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.f5648     Document Type: Review

References (49)

1. Vitart V, Rudan I, Hayward C., Gray NK, Floyd J, Palmer CN, et al SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet 2008; 40: 437-42. (Pubitemid 351450879)
2. Roddy E. Revisiting the pathogenesis of podagra: why does gout target the foot? J Foot Ankle Res 2011; 4: 13.
3. Zhang W, Doherty M, Pascual E., Bardin T, Barskova V, Conaghan P., et al.; EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR evidence based recommendations for gout. Part I: diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65: 1301-11. (Pubitemid 44641591)
4. Roddy E, Doherty M. Epidemiology of gout. Arthritis Res Ther 2010; 12: 223.
5. Edwards NL. The role of hyperuricemia and gout in kidney and cardiovascular disease. Cleveland Clin J Med 2008; 75: S13-16.
6. Mikuls TR, Farrar JT, Bilker W.B., Fernandes S., Schumacher HR Jr, Saag KG Gout epidemiology: results from the UK General Practice Research Database, 1990-1999. Ann Rheum Dis 2005; 64: 267-72. (Pubitemid 40197509)
7. Zhu Y, Pandya BJ, Choi HK Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. Am J Med 2012; 125: 679-687.e1.
8. Choi HK, Ford ES, Li C, Curhan G. Prevalence of the metabolic syndrome in patients with gout: the third national health and nutrition examination survey. Arthritis Rheum 2007; 57: 109-15.
9. Choi HK, Atkinson K, Karlson E.W., Willett W., Curhan G. Alcohol intake and risk of incident gout in men: aprospective study. Lancet 2004; 363: 1277-81. (Pubitemid 38496489)
10. Choi HK, Atkinson K, Karlson E.W., Willett W., Curhan G. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 2004; 350: 1093-103. (Pubitemid 38298989)
11. Choi HK, Curhan G. Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. BMJ 2008; 336: 309-12. (Pubitemid 351278368)
12. Choi HK, Willett W, Curhan G. Coffee consumption and risk of incident gout in men: a prospective study. Arthritis Rheum 2007; 56: 2049-55. (Pubitemid 47110404)
13. Emmerson BT, Nagel SL, Duffy D.L., Martin NG Genetic control of the renal clearance of urate: a study of twins. Ann Rheum Dis 1992; 51: 375-7.
14. Merriman TR, Dalbeth N. The genetic basis of hyperuricaemia and gout. Joint Bone Spine 2011; 78: 35-40.
15. Hueskes BA, Roovers EA, Mantel-Teeuwisse AK, Janssens H.J., van de Lisdonk EH, Janssen M. Use of diuretics and the risk of gouty arthritis: a systematic review. Semin Arthritis Rheum 2012; 41: 879-89.
16. Zhang W, Doherty M, Pascual E., Bardin T, Barskova V, Conaghan P., et al.; EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65: 1312-24. (Pubitemid 44620440)
17. Jordan KM, Cameron JS, Snaith M, Zhang W., Doherty M, Seckl J, et al British Society for Rheumatology and British Health Professionals in Rheumatology Standards, Guidelines and Audit Working Group (SGAWG). British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatol (Oxford) 2007; 46: 1372-4.
18. Roddy E, Mallen CD, Hider S.L., Jordan KP Prescription and comorbidity screening following consultation for acute gout in primary care. Rheumatol (Oxford) 2010; 49: 105-11.
19. Swan A, Amer H, Dieppe P. The value of synovial fluid assays in the diagnosis of joint disease: a literature survey. Ann Rheum Dis 2002; 61: 493-8. (Pubitemid 34539091)
20. Brauer GW, Prior IA A prospective study of gout in New Zealand Maoris. Ann Rheum Dis 1978; 37: 466-72. (Pubitemid 9074991)
21. Goldthwait JC, Butler CF, Stillman JS The diagnosis of gout; significance of an elevated serum uric acid value. N Engl J Med 1958; 259: 1095-9.
22. Urano W, Yamanaka H, Tsutani H., Nakajima H, Matsuda Y, Taniguchi A., et al. The inflammatory process in the mechanism of decreased serum uric acid concentrations during acute gouty arthritis. J Rheumatol 2002; 29: 1950-3. (Pubitemid 34988705)
23. Chowalloor PV, Keen HI A systematic review of ultrasonography in gout and asymptomatic hyperuricaemia. Ann Rheum Dis 2013; 72: 638-45.
24. Pineda C, Amezcua-Guerra LM, Solano C., et al Joint and tendon subclinical involvement suggestive of gouty arthritis in asymptomatic hyperuricemia: an ultrasound controlled study. Arthritis Res Ther 2011; 13: R4.
25. De Miguel E., Puig JG, Castillo C, et al Diagnosis of gout in patients with asymptomatic hyperuricaemia: a pilot ultrasound study. Ann Rheum Dis 2012; 71: 157-8.
26. Sutaria S, Katbamna R, Underwood M. Effectiveness of interventions for the treatment of acute and prevention of recurrent gout-a systematic review. Rheumatol (Oxford) 2006; 45: 1422-31. (Pubitemid 44605481)
27. Schumacher HR J.r., Boice JA, Daikh D.I., Mukhopadhyay S., Malmstrom K, Ng J, et al Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis. BMJ 2002; 324: 1488-92. (Pubitemid 34666615)
28. Rubin BR, Burton R, Navarra S., Antigua J, Londoño J, Pryhuber K.G., et al. Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. Arthritis Rheum 2004; 50: 598-606. (Pubitemid 38202232)
29. Man CY, Cheung IT, Cameron P.A., Rainer TH Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute goutlike arthritis: a double-blind, randomized, controlled trial. Ann Emerg Med 2007; 49: 670-7. (Pubitemid 46601694)
30. Janssens HJ, Janssen M, van de Lisdonk EH, van Riel PL, van Weel C. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet 2008; 371: 1854-60. (Pubitemid 351736009)
31. Khanna D, Khanna PP, Fitzgerald J.D., Singh MK, Mae S, Neogi T et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res 2012; 64: 1447-61.
32. Ahern MJ, Reid C, Gordon T.P., McCredie M., Brooks PM, Jones M. Does colchicine work? The results of the first controlled study in acute gout. Aust N Z J Med 1987; 17: 301-4. (Pubitemid 18014682)
33. Terkeltaub RA, Furst DE, Bennett K, Kook K.A., Crockett RS, Davis MW High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum 2010; 62: 1060-8.
34. British National Formulary. 10.1.4. Gout and cytotoxic-induced hyperuricaemia. Colchicine. June 2013.
35. Wechalekar MD, Vinik O, Schlesinger N., Buchbinder R. Intra-articular glucocorticoids for acute gout. Cochrane Database Syst Rev 2013; 4: CD009920.
36. Schlesinger N, Detry MA, Holland B.K., Baker DG, Beutler AM, Rull M, et al Local ice therapy during bouts of acute gouty arthritis. J Rheumatol 2002; 29: 331-4. (Pubitemid 34118783)
37. Rees F, Jenkins W, Doherty M. Patients with gout adhereto curative treatmentif informed appropriately: proof-of-concept observational study. Ann Rheum Dis 2013; 72: 826-30.
38. Dessein PH, Shipton EA, Stanwix A.E., Joffe BI, Ramokgadi J. Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study. Ann Rheum Dis 2000; 59: 539-43. (Pubitemid 30445833)
39. Kullich W, Ulreich A, Klein G. [Changes in uric acid and blood lipids in patients with asymptomatic hyperuricemia treated with diet therapy in a rehabilitation procedure]. Rehabilitation (Stuttg) 1989; 28: 134-7. (Pubitemid 19214469)
40. Taylor TH, Mecchella JN, Larson R.J., Kerin K., MacKenzie TA Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. Am J Med 2012; 125: 1126-3e7.
41. Li-Yu J., Clayburne G, Sieck M., Beutler A, Rull M, Eisner E., et al. Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? J Rheumatol 2001; 28: 577-80. (Pubitemid 32202663)
42. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004; 51: 321-5. (Pubitemid 38725128)
43. Perez-Ruiz F., Calabozo M, Pijoan J.I., Herrero-Beites AM, Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002; 47: 356-60. (Pubitemid 34856121)
44. Stamp LK, Taylor WJ, Jones P.B., Dockerty JL, Drake J, Frampton C, et al Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum 2012; 64: 2529-36.
45. Dalbeth N, Stamp L. Allopurinol dosing in renal impairment: walking the tight-rope between adequate urate-lowering and adverse events. Semin Dial 2007; 20: 391-5.
46. Borstad GC, Bryant LR, Abel M.P., Scroggie DA, Harris MD, Alloway JA Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol 2004; 31: 2429-32. (Pubitemid 39610535)
47. Tayar JH, Lopez-Olivo MA, Suarez-Almazor ME. Febuxostat for treating chronic gout. Cochrane Database Syst Rev 2012; 11: CD008653.
48. National Institute for Health and Care Excellence. Febuxostat for the management of hyperuricaemia in people with gout. TA164. 2011. www.nice.org.uk/nicemedia/live/12101/42738/42738.pdf.
49. Electronic Medicines Compendium (eMC). Summary of product characteristics: adenuric film-coated tablets. 2013. www.medicines.org.uk/emc/ medicine/22830/SPC.